These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18179676)

  • 1. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
    Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.
    Gonzales CR;
    Retina; 2005; 25(7):815-27. PubMed ID: 16205558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
    Yanagi Y; Aihara Y; Fukuda T; Hashimoto H
    Nippon Ganka Gakkai Zasshi; 2011 Sep; 115(9):825-31. PubMed ID: 22073599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    ; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
    Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
    Hopley C; Salkeld G; Mitchell P
    Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL; Colquitt J; Clegg AJ; Jones J
    Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
    Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
    Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T; Patel PJ; Tufail A; Rubin GS
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
    Atmani K; Coscas F; Coscas G; Soubrane G
    Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.